Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 4—April 2005

Dispatch

Ross River Virus Disease Reemergence, Fiji, 2003–2004

Philipp Klapsing*†, J. Dick MacLean*Comments to Author , Sarah Glaze‡, Karen L. McClean‡, Michael A. Drebot§, Robert S. Lanciotti¶, and Grant L. Campbell¶
Author affiliations: *Montreal General Hospital, Montreal, Quebec, Canada; †McGill University Health Centre, Montreal, Quebec, Canada; ‡Royal University Hospital, Saskatoon, Saskatchewan, Canada; §Health Canada, Winnipeg, Manitoba, Canada; and; ¶Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

Main Article

Table

Results of tests of patients’ serum for antibodies to selected alphaviruses*

IgM results†
PRNT titers‡
Patient Interval (d)§ RRV BFV RRV BFV SINV
1 10 Positive Negative 320 <10 <10
21 Positive Negative 1,280 <10 <10
141 Equivocal Negative 160 ND ND
2 16 Positive Negative 5,120 <10 ND
33 Positive Negative 5,120 <10 ND

*Ig, immunoglobulin; PRNT, plaque-reduction neutralization test; RRV, Ross River virus; BFV, Barmah Forest virus; SINV, Sindbis virus; ND, not done.
†IgM-capture enzyme immunoassay; samples tested at 1:400 dilution; positive samples had a positive-to-negative (P/N) absorbance ratio >3.0; equivocal samples had a P/N ratio 2.0–3.0 (10); no test for anti-SINV IgM was available.
‡90% plaque-reduction endpoints; >10 is considered positive (11).
§From onset of illness to serum collection.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO